Background {#Sec1}
==========

Mumps virus is a single-stranded negative sense RNA virus, and a member of the *Paramyxoviridae* family. This usually self-limited disease is endemic worldwide and occurs primarily in children and adolescents. Twenty-five to 30% of infections are asymptomatic \[[@CR1]\]. The most frequent clinical presentation is nonsuppurative parotitis, which occurs in up to 60-70% of persons infected \[[@CR1]\]. Meningitis, oophoritis and epididymo-orchitis represent the most common complications \[[@CR2]\]. Symptoms and complications might vary between immunized and unimmunized patients. Diagnosis relies on serology, viral culture, or molecular testing, such as real-time reverse-transcription polymerase chain reaction (rRT-PCR). If available, rRT-PCR is recommended on all patients being tested during the acute phase of illness because it has greater sensitivity than serology and, to a lesser extent, culture, as well as a faster turnaround time than culture \[[@CR3]--[@CR6]\]; moreover, serology has a low positive predictive value in a low prevalence setting \[[@CR7]\]. Although immunization with the live-attenuated mumps vaccine (Jeryl Lynn strain), first licenced in the United States in 1967, and in Canada in 1969, has markedly reduced the incidence of mumps to around 0.1 cases per 100,000 persons/year, outbreaks still occur \[[@CR8]\]. During the summer of 2009, a mumps outbreak that originated in New York State subsequently spread to Northeastern USA and Ontario, Canada \[[@CR2], [@CR9]\]. One hundred and thirty four cases of mumps were identified in Ontario, which has a population of 13 million inhabitants. The outbreak continued until June 2010 \[[@CR9]\]. As the microbiology reference laboratory for Ontario, Public Health Ontario Laboratory (PHOL) provides all mumps diagnostic testing for the province, including testing of all clinical specimens related to this outbreak. The aim of this study was to compare the performance of different diagnostic tests among patients under investigation for mumps in a population with high immunization rates, review testing practices of clinicians in Ontario, and describe the molecular characteristics of the mumps virus strain causing Ontario's 2009/2010 outbreak.

Methods {#Sec2}
=======

All clinical specimens from suspected mumps cases in the province of Ontario were sent to PHOL for testing, which included serology, and both viral culture and mumps rRT-PCR on buccal, oral/oropharyngeal, nasopharyngeal, throat/pharyngeal, urine, sputum and cerebrospinal fluid (CSF) specimens. Persons under investigation were classified using the Ontario Ministry of Health provincial case definition for mumps \[[@CR10]\], which was subsequently updated in 2014 \[[@CR11]\]. Clinical specimens of patients with suspected mumps submitted to PHOL for testing between September 1, 2009 and February 22, 2010 were included in the analysis. Patients with confirmed mumps based on clinical data and epidemiological link without laboratory testing were therefore not included in the study. Blood specimens submitted for diagnostic serology were tested for mumps IgG and IgM by a commercial indirect enzyme-linked immunoassay (ELISA) kit (Enzygnost Anti-Parotitis ELISA, Siemens AG, Munich, Germany). Qualitative IgG seroconversion was assessed if more than one serial blood specimen was submitted (an IgG-negative specimen followed by an IgG positive specimen collected at a later date). Respiratory, urine, and CSF specimens were tested by viral culture and rRT-PCR. Specimens submitted for virus culture were inoculated in rhesus monkey kidney primary cell lines and either WI-38 or MRC5 human embryonic lung fibroblast diploid cell lines (Quidel Corporation, San Diego, CA). Identification of mumps virus was performed by monitoring for cytopathic effect and haemadsorption using 0.6% guinea pig red blood cells. Cell lines showing syncytia or a positive haemadsorption test were tested by an indirect immunofluorescent assay (IFA) for confirmation; more specifically, the IFA used a mumps monoclonal murine IgG1k antibody made against the Enders mumps strain and targeting two different epitopes of the fusion protein (Light Diagnostics™ Mumps IFA Kit, EMD Millipore Corporation, CA, USA). Initially negative cultures were passaged after 10 days, and reported negative following a further 7 days incubation (total incubation time 17 days). Cultured specimens were only considered mumps-positive if the mumps antigen was detected by IFA. The rRT-PCR was conducted at PHOL using an in-house assay adapted from protocols developed by Canada's National Microbiology laboratory (NML) and the US Centers for Disease Control (CDC), which targets the fusion (F1) and small hydrophobic (SH) genes \[[@CR12], [@CR13]\]. Genotyping was performed at NML using RT-PCR and sequencing of the entire small hydrophobic gene (316 nucleotides) \[[@CR14]\]. Whole genome sequencing (WGS) was performed on four outbreak and three sporadic viral culture Ontario isolates using overlapping primers folllowed by either next-generation sequencing using the Illumina MiSeq (Illumina Inc. San Diego, California, USA) or Sanger sequencing using the ABI 3730 DNA Analyzer (Applied Biosystems ™, Foster City, California, USA), as previously described \[[@CR15]\] and compared to mumps reference strains \[[@CR16]\].

Comparisons of assay's sensitivity were performed using McNemar's or Chi-square tests using SAS statistical software (version 9.2). *P*-values \< 0.05 were considered significant.

Results {#Sec3}
=======

Diagnostic testing {#Sec4}
------------------

Eight hundred and fifty-three blood specimens were received from 698 patients for IgM serology testing, of which 255 patients had 372 specimens submitted for both viral culture and rRT-PCR. Among those, 35/698 tested patients (5%) were IgM-positive, 39/255 tested patients (15%) were culture positive for mumps virus, and 47/255 tested patients (18%) were rRT-PCR-positive (Table [1](#Tab1){ref-type="table"}). The most frequent specimen collection site for rRT-PCR was buccal (*n* = 158; 42.5% of rRT-PCR specimens), followed by urine (*n* = 146; 39.3% of rRT-PCR specimens). IgM serology was positive in 5.7% (49/853) of tested specimens whereas culture and rRT-PCR were positive in 13% (47/372) and 17% (62/372) tested specimens, respectively. Buccal swab rRT-PCR had the highest positivity (21%) among all specimen types (Table [1](#Tab1){ref-type="table"}). Twenty-six percent (23/90) of patients who had more than one serum specimen submitted demonstrated mumps IgG seroconversion.Table 1Summary of specimens tested for mumps by serology, viral culture and rRT-PCRSpecimens positive/tested (% pos)^b^Persons positive/tested (% pos)^c^IgM Serology49/853 (6%)35/698 (5%)Viral Culture47/372 (13%)39/255 (15%)rRT-PCR62/372 (17%)47/255 (18%) Buccal33/158 (21%) Urine19/146 (14%) Oral/Oropharyngeal1/11 (9%) Throat/Pharyngeal3/24 (13%) Nasopharyngeal0/8 (0%) CSF1/1 (100%) Sputum0/1 (0%) Other swab^a^5/23 (22%)*rRT-PCR* real-time reverse-transcription polymerase chain reaction, *CSF* cerebrospinal fluid^a^Collection site not provided^b^Serology vs culture: *P* \< 0.0001; Serology vs rRT-PCR: *P* \< 0.0001; Culture vs rRT-PCR: *P* = 0.12^c^Serology vs culture: *P* \< 0.0001; Serology vs rRT-PCR: *P* \< 0.0001; Culture vs rRT-PCR: *P* = 0.344

Assay comparison was conducted for all patients who had more than one test done and showed that rRT-PCR was superior to serology (Table [2](#Tab2){ref-type="table"}); it also confirmed that buccal rRT-PCR was superior to urine rRT-PCR.Table 2Comparison of test performance in mumps positive patients tested by more than one testing modalityPositive mumps test (denominator)Comparator test positivity (numerator)Buccal rRT-PCRUrine rRT-PCRAny rRT-PCRAny virus cultureIgMIgG seroconversionBuccal rRT-PCR positive14/27 (51.9%)33/33 (100%)29/33 (87.9%)8/24 (33.3%)4/23 (17.4%)Urine rRT-PCR positive14/17 (82.4%)19/19 (100%)15/18 (83.3%)8/14 (57.1%)3/25 (12.0%)Any rRT-PCR positive33/40 (82.5%)19/36 (52.8%)37/45 (82.2%)13/31 (41.9%)6/30 (20.0%)Any virus culture positive29/33 (87.9%)15/29 (51.7%)37/39 (94.9%)9/27 (33.3%)4/30 (13.3%)IgM positive8/16 (50.0%)8/14 (57.1%)13/19 (68.4%)9/17 (52.9%)10/90 (11.1%)IgG seroconversion4/8 (50.0%)3/10 (30.0%)6/10 (60%)4/9 (44.4%)10/23 (43.5%)*rRT-PCR* real-time reverse-transcription polymerase chain reaction

Among the 47/255 rRT-PCR positive patients, 31 (66%) had an IgM test performed, of which 13 (42%) were positive, 14 (45%) negative, and four (13%) indeterminate. Surprisingly, only 19/35 (54%) IgM positive patients had specimens submitted for rRT-PCR and/or culture.

Among the 105 patients who had both buccal and urine specimens submitted, rRT-PCR was positive in buccal and/or urine specimen in 30 (29%). rRT-PCR was positive for buccal specimens only, urine specimens only and both urine and buccal specimens in 13, 3 and 14 cases, respectively; therefore, buccal swabs detected 27/30 (90%) of rRT-PCR positive specimens, compared to 17/30 (57%) for urine (*p* = 0.02). Time between symptom onset and collection date was poorly reported. Only 12.4% (64/517) of patients who were IgM negative, and had no rRT-PCR or culture testing done, had time since symptom onset reported. Median duration from illness onset to collection date in this group was 4 days (range 0-27 days). For IgM-positive patients, 13/35 (37%) had a reported time since symptom onset, with a median duration from illness onset to collection date of 4 days (range 3-26 days).

Phylogenetic analysis {#Sec5}
---------------------

Genotyping of the SH gene, performed at the Public Health Agency of Canada's NML*,* confirmed that all tested outbreak and sporadic strains were genotype G; all were \> 99% identical to a predominant circulating strain identified in Canada in 2007, with a difference of not more than two nucleotides. The four mumps outbreak isolates which underwent WGS (GenBank accession numbers: KY680537.1, KY680538.1, KY680539.1 and KY680540.1) had between 99.8-99.9% nucleotide identity with sequences from the New York 2009-2010 outbreak (GenBank accession numbers: JX287389.1, JX287391.1, JX287390.1 and JX287387.1), confirming that the same strain was circulating for the Ontario, Canada and New York outbreaks (Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}, Table [3](#Tab3){ref-type="table"}). Fifteen synonymous single-nucleotide polymorphisms were observed within the whole genome of Ontario's outbreak strains and nucleotide identity of 99.9% was obtained. However, nucleotide identity within all seven Ontario strains (including non outbreak strains KY006856.1, KY006857.1 and KY006858.1) were calculated to be 98.7-99.8%. Nucleotide and amino acid identity between the Ontario outbreak strains and the Jeryl Lynn vaccine strain components varied between genes, ranging from 85.0 to 94.5% and from 82.4 to 99.4%, respectively (Table [4](#Tab4){ref-type="table"}). Homology of the HN protein, the main immunogenic mumps virus protein, was found to be 94.5 and 95.3%, when compared to Jeryl Lynn vaccine major and minor components, respectively.Fig. 1Whole genome sequencing (WGS) phylogenetic tree. The WGS phylogenetic tree was constructed using the nearly complete genomes (15,264 nucleotides) of four genotype G mumps outbreak isolates from Ontario (GenBank accession numbers: KY680537.1, KY680538.1, KY680539.1 and KY680540.1), three sporadic Ontario isolates (GenBank accession numbers: KY006856.1, KY006857.1 and KY006858.1) and representatives of other genotypes available in NCBI's GenBank sequence database. The phylogenetic tree containing 37 strains was reconstructed using the Neighbor-Joining method and Maximum Composite Likelihood was used to compute the evolutionary distances. The statistical significance of the phylogenies constructed was estimated by bootstrap analysis of 1000 pseudo-replicate data sets (bootstrap values of \> 70% are given at each node). The horizontal length of the bar denotes the nucleotide changes per site (MEGA version 6.06 software package). Outbreak and non-outbreaks isolates identified at Public Health Ontario Laboratory in 2010 are labelled with red and blue circles respectivelyFig. 2Small hydrophobic (SH) gene sequencing phylogenetic tree. The SH phylogenetic tree was constructed based on the 316 nucleotides of the entire SH gene of four genotype G mumps outbreak isolates from Ontario (GenBank accession numbers: KY680537.1, KY680538.1, KY680539.1 and KY680540.1), three sporadic Ontario isolates (GenBank accession numbers: KY006856.1, KY006857.1 and KY006858.1) and representatives of other genotypes available in NCBI's GenBank sequence database. The phylogenetic tree containing 37 strains was reconstructed using the Neighbor-Joining method and Maximum Composite Likelihood was used to compute the evolutionary distances. The statistical significance of the phylogenies constructed was estimated by bootstrap analysis of 1000 pseudo-replicate data sets (bootstrap values of \> 70% are given at each node). The horizontal length of the bar denotes the nucleotide changes per site (MEGA version 6.06 software package). Outbreak and non-outbreaks isolates identified at Public Health Ontario Laboratory in 2010 are labelled with red and blue circles respectivelyTable 4Identity between Jeryl Lynn vaccine mumps strain and Ontario mumps whole genome sequencesGeneJL Major % identityJL Minor % identityNucleotide (%)Amino acid (%)Nucleotide (%)Amino acid (%)Nucleocapsid Protein (NP)94.498.394.598.3Phosphoprotein (P)92.7--92.889.6--89.991.9--92.087.5--87.8Matrix (M)93.2--93.399.292.9--93.199.4Fusion (F)92.9--93.194.7--95.194.3--94.596.0--96.4Small Hydrophobic (SH)87.385.985.082.4Hemagglutinin--Neuraminidase (HN)91.094.591.995.3Large Protein (L)94.098.8--98.994.2--94.398.7--98.8*JL* Jeryl LynnTable 3Percentage of whole genome sequence identity between mumps sequencesOutbreak and non-outbreaks isolates identified at Public Health Ontario Laboratory in 2010 are labelled in red and blue respectively

Discussion {#Sec6}
==========

Mumps outbreaks continue to occur worldwide, including in populations with adequate immunization schedules and coverage. In 2016, more than 6000 cases of mumps were reported in the USA, the highest in 10 years \[[@CR17]\]. In 2017, more than 5600 cases were reported in the USA, mostly related to an outbreak also involving Canada \[[@CR17]\]. The outbreak that started in New York in 2009 and subsequently reached Ontario is one of the biggest reported outbreaks since universal immunization, with more than 3500 reported cases in the USA alone \[[@CR2]\]. Phylogenetic analyses confirmed that the strain responsible for the outbreak in Ontario was similar to the one causing the outbreak in New York \[[@CR2]\]. Moreover, WGS confirmed that outbreak isolates were \> 98.7% similar to sporadic isolates, suggesting that the outbreak strain has been previously circulating. The presumed index case of the New York outbreak was a child who recently returned from the United Kingdom where a large outbreak was happening \[[@CR18]\].

The outbreak in Ontario occurred in a population where 14% of cases were unimmunized, whereas 55 and 28% of cases had previously received 1 and 2 doses, respectively \[[@CR9]\]. Therefore, the outbreak occured in a context of suboptimal immunization as well as possible waning of immunity. The relatively low percentage of sequence homology between our strain and the Jeryl Lynn vaccine strain is related to the fact that they belong to genotypes G and A, respectively, which has been suggested as a potential cause of suboptimal vaccine effectiveness \[[@CR19], [@CR20]\]. However, additional studies have shown that vaccine-induced antibody effectively neutralizes wild-type virus \[[@CR19], [@CR21], [@CR22]\]. Consequently, the pathophysiology of mumps vaccine failure is still unclear.

Our study demonstrated that rRT-PCR was the most sensitive assay for mumps detection. Viral culture was slightly less sensitive, and this difference did not reach statistical significance. However, IgM serology was significantly less sensitive than both rRT-PCR and viral culture. Our observed order of assay sensitivity is consistent with large studies with \> 80 laboratory confirmed cases \[[@CR3], [@CR5], [@CR23], [@CR24]\]. In addition, a number of studies have shown a better sensitivity of rRT-PCR compared to IgM serology \[[@CR4], [@CR25]--[@CR32]\] and, to a lesser extent, culture \[[@CR12], [@CR25], [@CR26]\]. However, inconsistent findings in smaller studies has been observed where IgM yielded similar or better sensitivity than culture \[[@CR25], [@CR26], [@CR33]\] or RT-PCR \[[@CR34]\]. More than 3500 cases were confirmed in the USA during the 2009-2010 outbreak that reached Ontario \[[@CR2]\]. Among the 1648 tested patients in the USA, 831 (50%) were positive by at least one assay. In this large sample, rRT-PCR was the most sensitive assay with 68% positivity (373/550) among cases who had rRT-PCR testing, compared to 64% (283/443) and 35% (550/1563) of cases who underwent cell culture and IgM testing, respectively. The discrepant sensitivity of RT-PCR, culture and serology between the above-mentioned studies could be a result of confounding by the different vaccination status and different time between symptom onset and specimen collection among the studied populations. Indeed, previously immunized patients are less likely to develop an IgM response when subsequently exposed to mumps \[[@CR2], [@CR6]\]. Moreover, rRT-PCR and culture are more likely to be positive if specimens were collected in the first 2 days after parotitis onset \[[@CR2], [@CR6]\], whereas IgM is more likely to be positive if collected ≥ 3 days after symptom onset \[[@CR6]\]. Among the same population, Rota et al. showed that sensitivity of rRT-PCR was higher than serology from day 0 to day 2 after symptom onset, whereas the sensitivity of serology was higher than rRT-PCR from day 3 onwards \[[@CR6]\]. The fact that rRT-PCR yield was highest during day one to three after parotitis onset and decreased afterwards was confirmed in two other studies, using rRT-PCR \[[@CR27]\] and RT-PCR \[[@CR23]\], respectively.

Additional testing showed that rRT-PCR and IgM sensitivity varied significantly using different assays \[[@CR6], [@CR35]\]. In the Ontario outbreak, negative IgM tests in our confirmed cases could not be explained by early collection of specimens, as we observed a median duration of 4 days from symptom onset to blood collection, which should have been ample time for IgM to develop. The low sensitivity of IgM serology may also be confounded by immunization status. It has been suggested that immunized individuals have modified B cell responses that allow for the rapid generation of IgG antibodies and a blunted, or absent IgM response, when exposed to mumps virus \[[@CR24]\]. This phenomenon could also result in a lack of IgG seroconversion being observed following mumps infection in previously immunized patients, due to an IgG boost occurring prior to clinical presentation. Studies performed in the USA during the 2009-2010 outbreak showed that IgM serology was less likely to be positive among immunized (26%) than unimmunized patients (76%, *P* \< 0.05), whereas immunization status had no influence on rRT-PCR and culture results \[[@CR2], [@CR6]\]. This low yield of IgM in immunized patients during an outbreak has been reported in other studies \[[@CR24], [@CR36]\].

Our study also confirmed that rRT-PCR sensitivity varied with specimen type and was higher for buccal than oropharyngeal swabs or urine. This is consistent with previous studies showing that saliva swabs performed better than pharyngeal swabs, whereas test sensitivity was lowest for urine \[[@CR4], [@CR23], [@CR37]\]. Similarly, Hindiyeh et al. showed that RT-PCR sensitivity was higher with pharyngeal or parotid fluid than urine \[[@CR38]\].

The main limitation of the study is the relative lack of clinical data about the studied population, such as symptoms at disease onset. This is related to the fact that clinicians in the community forward specimens to our laboratory for mumps testing, often without providing significant clinical data. As a consequence, it was not possible to know precisely the immunization status of the tested patients which would have allowed comparison of diagnostic methods between immunized and unimmunized patients; however, the immunization status of the same population at this time was reported in another publication, showing that 86% of the population had received at least one dose and more than 55% two doses \[[@CR9]\]. Similarly, the time between symptom onset and specimen collection was provided for a minority of patients only. As these data might influence serology and RT-PCR sensitivity, it would have provided important additional information in this setting. As it has been shown that a rRT-PCR targeting the nucleoprotein gene was more sensitive than a rRT-PCR targeting the SH gene \[[@CR6]\], the fact that our assay targeted the F1 and SH genes might also be a potential limitation of the study.

Despite the abundance of previous data showing that RT-PCR, and to a lesser extent viral culture, are the most sensitive detection methods, most patients in our study had serology testing during the acute illness without any rRT-PCR or culture testing. This testing pattern was also observed in the US outbreak and may reflect the current practice in North America. During the same outbreak in the USA, IgM serology was used in 95% (*n* = 1563) of the 1648 tested patients, whereas rRT-PCR and viral culture were used in only 33% (*n* = 550) and 27% (*n* = 443), respectively \[[@CR2]\]. This testing practice is in contrast to a 2009 Australian study that showed that RT-PCR was the most frequently used diagnostic method during a mumps outbreak in that country \[[@CR3]\]. The current CDC guidelines recommend to perform serology as well as rRT-PCR or culture, but emphasize the lower yield of urine compared to buccal specimens \[[@CR39]\]. On the other hand, the Public Health Agency of Canada recommends to perform serology as well as buccal and urine rRT-PCR but no longer recommends culture in the current guidelines \[[@CR40]\]. Clinician education is needed to increase awareness of the availability, better sensitivity and test performance of rRT-PCR compared to serology.

Compared to rRT-PCR, IgM serology has lower sensitivity and may be highly influenced by immunization status. As such, rRT-PCR should be considered as the gold standard for mumps detection because of its high sensitivity and its quick turnaround time. However, it is not uncommon that patients with negative rRT-PCR \[[@CR27], [@CR29], [@CR32]\] or RT-PCR \[[@CR41]\], have positive IgM. As a consequence, these two assays are somewhat complementary, as IgM yield increases with time following symptom onset, when RT-PCR yield decreases. However, clinicians should keep in mind the poor positive predictive value of IgM when used in a low prevalence setting such as North America, for example in the absence of an outbreak \[[@CR7]\]. Due to the impact of time since symptom onset and the relative sensitivity of rRT-PCR and serology, we therefore emphasize the need to continue educating healthcare providers of the importance of submitting both buccal swab and urine specimens for rRT-PCR, in addition to a specimen for IgM/IgG serology when mumps is suspected, in accordance with current guidelines.

Conclusions {#Sec7}
===========

This study confirms that rRT-PCR has higher sensitivity than serology, and is still underutilized for the diagnosis of mumps. This work also confirms the superiority of buccal rRT-PCR compared to urine rRT-PCR. Phylogenetic analysis confirmed the discrepancies in nucleotide and amino acid homology between outbreak and vaccine strains. Further work is needed to better understand the suboptimal match of the HN gene between the outbreak strain and the Jeryl Lynn vaccine strain, in order to better protect vaccinated individuals.

CPE

:   Cytopathic effect

CSF

:   Cerebrospinal fluid

F1

:   Fusion gene

PHOL

:   Public Health Ontario Laboratory

rRT-PCR

:   Real-time reverse-transcriptase PCR

SH

:   Small hydrophobic gene

WGS

:   Whole genome sequencing

Funding {#FPar1}
=======

This work was supported by Public Health Ontario. The funding source had no involvement in study design, data collection, analysis or interpretation, as well as manuscript writing and decision to submit the manuscript.

Availability of data and materials {#FPar2}
==================================

All data generated or analysed during this study are included in this published article.

Depositories {#FPar3}
============

The GenBank accession numbers for the four outbreak and the three sporadic isolates sequenced in this study are KY680537.1/KY680538.1/KY680539.1/KY680540.1 and KY006856.1/KY006857.1/KY006858.1 respectively.

CR, DA, JG, and TM designed the study. AE, CR, KO, EL, RH, EK and JM performed the laboratory analyses. AL, AR, CR, DA, EK, JM, JG, and TM analysed the data. AL, AE, KO, EL, RH, JG, and TM wrote the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate {#FPar4}
==========================================

These data are also used for routine laboratory surveillance, which is a mandate of PHOL. Therefore, consultation with our organization's privacy office or ethics committee was not required. To protect patient privacy and confidentiality, data are reported in an aggregated anonymized format.

Competing interests {#FPar5}
===================

JB Gubbay has received research grants from GlaxoSmithKline Inc. and Hoffman-La Roche Ltd. to study antiviral resistance in influenza, and from Pfizer Inc. to conduct microbiological surveillance of *Streptococcus pneumoniae*. The authors declare that they have no competing interests.

Publisher's Note {#FPar6}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
